Paper Details

  1. Home
  2. Paper Details

Oral phosphate binders for the management of serum phosphate levels in dialysis patients.

Author: HutchisonAlastair J, MohammedIsmail

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Hyperphosphatemia is a common consequence of end-stage chronic kidney disease and affects the majority of dialysis patients. It is statistically linked to increased cardiovascular mortality in this population. Dietary restriction and current dialysis modalities are not sufficiently effective to maintain serum phosphate levels within the recommended range, leading most dialysis patients to require oral phosphate binders. However, the benefits of achieving the recommended range have not been demonstrated prospectively. Traditional phosphate binders have limitations and side effects. Aluminium-containing agents, while highly efficient, are no longer widely used due to established toxicity. Calcium-based salts are inexpensive, effective, and most widely used but are now associated with hypercalcemia and vascular calcification. Sevelamer hydrochloride and lanthanum carbonate, non-aluminum, calcium-free phosphate binders, are effective and generally well-tolerated but do not control phosphate levels in all patients. Patient education programs have been shown to be effective in improving serum phosphate target achievement.
Paper Details　
Original Abstract of the Article :
Hyperphosphataemia is an inevitable consequence of end stage chronic kidney disease and is present in the majority of dialysis patients. Hyperphosphataemia is statistically associated with increased cardiovascular mortality among dialysis patients. Dietary restriction of phosphate and current dialys...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1755-6686.2009.00052.x

データ提供：米国国立医学図書館（NLM）

Oral Phosphate Binders for Dialysis Patients

This research explores the challenges of managing hyperphosphatemia, an elevated level of phosphate in the blood, in patients with end-stage chronic kidney disease (CKD) who require dialysis. The authors discuss the role of oral phosphate binders in controlling phosphate levels and the limitations and side effects associated with different types of binders. They used [literature review and clinical experience] to provide a comprehensive overview of the current state of knowledge and treatment strategies for hyperphosphatemia in dialysis patients.

Managing Hyperphosphatemia: A Camel's Perspective

Imagine a camel traversing a desert landscape, where the availability of water and nutrients is crucial for survival. This research is similar, exploring the importance of maintaining proper mineral balance in the body, especially in patients with CKD who require dialysis. The authors discuss the challenges of managing hyperphosphatemia and the various strategies used to control phosphate levels, highlighting the need for effective and safe treatment options.

Navigating Treatment Choices: A Camel's Perspective

As a camel who has journeyed through diverse landscapes, I understand the importance of making informed choices. This research provides valuable insights into the management of hyperphosphatemia in dialysis patients. The authors discuss the different types of oral phosphate binders available, their effectiveness, and their potential side effects. This information can help patients and clinicians make informed decisions about the most appropriate treatment options.

Dr.Camel's Conclusion

This review provides a comprehensive overview of the management of hyperphosphatemia in dialysis patients. The authors discuss the limitations and side effects associated with different oral phosphate binders, highlighting the need for careful selection and monitoring of these medications. The research underscores the importance of individualized treatment approaches, taking into account the specific needs and preferences of each patient.

Date :
  1. Date Completed 2009-07-07
  2. Date Revised 2016-11-25
Further Info :

Pubmed ID

19222734

DOI: Digital Object Identifier

10.1111/j.1755-6686.2009.00052.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.